Different COVID-19 outcomes among systemic rheumatic diseases: a nation-wide cohort study
Authors' conclusion
COVID-19 may have a more severe impact in patients with systemic rheumatic disease than in the general population.
Study context
- Population
- All adults with RA, AS, PsA, SLE and SSc under treatment (median age 67.5, 51.2, 58.1, 56.2 and 62.2 years, respectively), 1 March 2020 to 28 February 2021patients with rheumatic disease
- Participants
- 74,970 adults
- Exposure
- RA, AS, PsA, SLE and SSc vs matched general population comparators
- Outcome
- COVID-19-associated hospitalization and death
- Follow-up
- First year of the pandemic
Methodological detailsmatched (1:5) on age, sex and region of domicile, interlinked nationwide electronic registries
- Matched (1:5) on age, sex and region of domicile
- Interlinked nationwide electronic registries
Main finding
As reported in the abstract
Each group vs general populationEstimate (CI)
RA
IRR (hospitalization) 1.71(1.50–1.95)
SLE
IRR (hospitalization) 2.0(1.4–2.7)
SSc
IRR (hospitalization) 2.28(1.29–3.90)
RA
IRR (death) 1.91(1.46–2.49)
Observational data: associations, not effects.
Further findings
| Outcome | OR (CI) | |
|---|---|---|
| COVID-19-associated death among SARS-CoV-2-infected subjectsRAvs General populationAdjusted for age and gender | 1.47 (1.11–1.94) | |
| COVID-19-associated death among SARS-CoV-2-infected subjectsSScvs General populationAdjusted for age and gender | 2.92 (1.07–7.99) | |
| 0.10.31310Odds ratio (log scale) |
| Outcome | IRR (pandemic year) |
|---|---|
| All-cause mortality vs general population, pandemic year vs 2019RA vs General population · 2019: 0.59 | 0.71 |
| All-cause mortality vs general population, pandemic year vs 2019SSc vs General population · 2019: 4.36 | 1.94 |
Original publication
Different COVID-19 outcomes among systemic rheumatic diseases: a nation-wide cohort study. Rheumatology (Oxford). Published 3 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →